Preliminary Q1 2026 Results Conference Call Presentation: Tuesday, April 28, 2026

Published: 2026-04-28 09:19:13 ET QGEN

Published on 04/28/2026 at 09:19 am EDT

April 27, 2026

Q1 2026: Overview

Preliminary Q1 2026: Mixed net sales trends, adj. EPS achieving outlook

$492 mn net sales (+2% actual, -1% CER vs. ≥1% CER outlook)

$0.54 CER adjusted diluted EPS in line with outlook

Strong growth among key pillars, led by Sample technologies and QIAcuity

Sample technologies: +9% CER growth, +3% CER growth excluding Parse

Net sales

In $ millions

+2% /

492

483

-1% CER

Adjusted EPS

In $ per share

QIAcuity: Double-digit CER growth on instrument placements and consumables expansion

QDI: Solid single-digit growth

QuantiFERON sales impacted by lower immigration testing demand

-5% CER decline mainly due to sharply lower immigration testing (U.S./Middle East)

Solid trends in other key patient testing groups and key markets worldwide

0.55

0.54

Ongoing solid profitability

27.4% adj. operating income margin

Absorbed about 3.4 ppts headwinds from tariffs, currency movements and acquisitions

Updated FY 2026 outlook

~+1-2% CER net sales growth, led by ~+4% CER growth in H2 2026

≥$2.43 CER adjusted diluted EPS

Q1 2025

Q1 2026

Q1 2025

Q1 2026

Q1 2026: Sales performance and key developments

Sales by product group

(In $ millions at actual rates)

-1% CER(1)

185

170

150

187

483 492

Sample technologies

• +9% CER growth, +3% CER growth excl. Parse

Parse integration progressing well, on track to exceed

~$40 mn FY 2026 sales target

Q1 2025

Q1 2026

Sample technologies

Diagnostic solutions

PCR / Nucleic

acid amplification Genomics / NGS

Other

QuantiFERON • -5% CER decline amid sharp drop in immigration testing

Strong uptake of new high-throughput Diasorin chemistry

QIAstat-Dx • -1% CER decline as expected vs. strong Q1 2025

Consumables led by double-digit GI and Meningitis panel growth

QIAcuity • Double-digit CER growth led by consumables and instruments

Continued adoption supported by all regions

Solid single-digit CER growth driven by clinical double-digit growth

QDI

Advancing portfolio with AI-enhanced products

(1) Q1: Net sales $477 million CER (-1% at constant exchange rates, +2% at actual rates)

Q1 2026: Portfolio developments

Sample technologies - Parse:

Advancing scalable single-cell sequencing

Launch of Evercode® Whole Transcriptome chemistry

Enables scalability of up to 5 million cells with improved sensitivity and cell recovery

Simplified, automation-ready workflow with lower sequencing costs

Oncology portfolio:

Addressing key oncology research needs

Expansion of genomic profiling solutions in oncology

Genomics/NGS: New QIAseq panels enabling broad genomic profiling

QDI: Introduction of AI-grounding solution for unified drug discovery support in research

QIAstat-Dx:

Advancing syndromic testing solutions

Launch of new QIAstat-Dx panels and QIAstat-Dx Rise menu expansion

Blood culture panel: Entry into bloodstream infection testing (Europe)

GI panels: Menu expansion on QIAstat-Dx Rise (U.S.)

FY 2026 sales outlook: Updated perspectives

≥+5% CER ~ -1.5 ppts

~ -2 ppts

~+1-2% CER

•

Reduced immigration testing demand

(U.S. / Middle East)

•

Cautious U.S. Life Sciences capital spending

OEM customer ordering trends

Middle East conflict

2026 outlook (February)

QuantiFERON Life Sciences / Geopolitical uncertainties

Updated 2026 outlook (April)

Updated FY 2026 sales outlook: ~+1-2% CER growth

CER - Constant exchange rates | ppts - Percentage points

FY 2026: Leveraging a solid portfolio to drive growth

Sample tech

QuantiFERON

QIAcuity

QIAstat-Dx

QDI

Growth pillars total sales (CER)

2026 CER

targets

(February 2026)

~$1.61 bn

~7% CER growth

~$720 mn

~$535 mn

~$100 mn

~$160 mn ~$125 mn

Updated

Updated 2026 CER

targets

(April 2026)

~$1.64 bn

~$720 mn

~$500 mn

~$100 mn

~$160 mn ~$125 mn

Q1 2026: 4 out of 5 pillars delivered or exceeded expectations

CER - Constant exchange rates

2026 sales outlook: H1 vs. H2 updated perspectives

Updated

~+0.5 ppts ~+4% CER

~+1 ppt

~+2 ppts

~ -1-2% CER

H1 2026 growth outlook

End of NeuMoDx, Dialunox headwind

New Sample tech systems, new product launches(1)

QuantiFERON returning to growth

Better U.S. Life Science environment and Parse

H2 2026 growth outlook

Multiple levers to improve sales trends in H2 2026

CER - Constant exchange rates I ppts - Percentage points I (1) QIAstat-Dx and QIAcuity launches

Q2 and FY 2026: Updated outlook and assumptions

(As of April 27, 2026)

Q2 2026 outlook

FY 2026 outlook

~ -2% CER

Positive impact of ~+1 ppt

≥$0.60 CER

Neutral

~208 million

~+1-2% CER

Positive impact of ~+1 ppt

≥$2.43 CER

Neutral

~209 million

Net sales

Anticipated currency impact(1)

Adjusted diluted EPS(2)

Anticipated currency impact(1)

Adjustments to operating income (In $ millions):

Business integration and acquisition-related items

~$8 mn

~$25 mn

Restructuring-related items

~$7 mn

~$45 mn

Amortization of acquired intellectual property

~$15 mn

~$62 mn

Adjusted tax rate (%)

~17-18%

Weighted average number of diluted shares outstanding (Based on $40.00 share price)

Based on exchange rates as of April 27, 2026.

QIAGEN reports adjusted results to provide additional insight into its performance. Adjusted results are non-GAAP financial measures that QIAGEN believes should be considered in addition to reported results prepared in accordance with GAAP but should not be considered as a substitute. QIAGEN believes certain items should be excluded from adjusted results when they are outside of ongoing core operations, vary significantly from period to period, or affect the comparability of results with competitors and its own prior periods. Furthermore, QIAGEN uses non-GAAP and constant currency financial measures internally in planning, forecasting and reporting, as well as to measure and compensate employees. QIAGEN also uses adjusted results when comparing current performance to historical operating results, which have consistently been presented on an adjusted basis.

Q1 2026: Maintaining solid profitability while investing in future growth

Adjusted operating income margin

29.8% ~-1.5 ppts

~-0.7 ppts

~-1.2 ppts

~+1 ppt

~27.4%

Q1 2025

Tariffs

FX Acquisitions

Efficiency program Q1 2026

ppts- Percentage points

Your contacts

Calendar

Q1 2026 full results

May 6, 2026

QuantiFERON Spotlight Session

May 7, 2026

E-mail:

[email protected]

Internet: corporate.QIAGEN.com

Annual General Meeting June 2026

Q2 2026 results

August 2026

Share information

NYSE: QGEN

Frankfurt:

QIA

ISIN / CUSIP:

NL0015002SN0 / N72482 156

WKN:

A41HBE

www.linkedin.com/company/qiagen

www.x.com/QIAGEN

www.facebook.com/QIAGEN

www.youtube.com/user/QIAGENvideos

Daniel Wendorff

Vice President

Head of Investor Relations

Phone: +49 2103 29 11322

E-mail: [email protected]

Dr. Domenica Martorana

Associate Director Investor Relations

Phone: +49 2103 29 11244

E-mail: [email protected]

Alexandra Koenig

Coordinator Investor Relations

Phone: +49 2103 29 11709

E-mail: [email protected]

April 27, 2026

Disclaimer

Qiagen NV published this content on April 28, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 28, 2026 at 13:18 UTC.